Tenon Medical SEC Filings

Tenon Medical, Inc. updated its leadership compensation and extended its executive chairman’s consulting agreement. The board’s Compensation Committee approved a 2026 Executive Compensation Plan that raises annual base salaries for CEO Steven M. Foster to $420,000, CFO Kevin Williamson to $330,750, and COO Richard Ginn to $304,500, each reflecting a 5% increase effective March 1, 2026. The plan also increases their annual bonus opportunities, with Mr. Foster eligible for 50% of base salary and Mr. Williamson and Mr. Ginn each eligible for 35%, all tied to mutually agreed milestones. In addition, they may earn a second milestone-based bonus of up to $100,000, $70,000, and $50,000, respectively. Separately, the company amended Executive Chairman Richard Ferrari’s consulting agreement, extending it for one year from May 7, 2026 to May 6, 2027, with compensation of $45,000 per quarter, or $180,000 annually.

Tenon Medical, Inc. reported that its Board of Directors approved Amendment No. 1 to the company’s Bylaws, effective June 10, 2026. The amendment lowers the stockholder meeting quorum requirement from a majority of eligible votes to not less than 33 1/3% of votes entitled to be cast, consistent with Nasdaq Listing Rule 5620.

The amendment also revises voting provisions so that holders of shares representing not less than a majority of the votes present at a meeting, rather than a majority of all outstanding shares, may decide that voting must be by written ballot and overseen by inspectors of election.

Tenon Medical, Inc. reported that its Board of Directors approved Amendment No. 1 to the company’s Bylaws, effective June 10, 2026. The amendment lowers the stockholder meeting quorum requirement from a majority of eligible votes to not less than 33 1/3% of votes entitled to be cast, consistent with Nasdaq Listing Rule 5620.

The amendment also revises voting provisions so that holders of shares representing not less than a majority of the votes present at a meeting, rather than a majority of all outstanding shares, may decide that voting must be by written ballot and overseen by inspectors of election.

Tenon Medical, Inc. reported receiving a Nasdaq notice that it no longer meets the Nasdaq Capital Market’s minimum stockholders’ equity requirement. Nasdaq Listing Rule 5550(b)(1) requires at least $2,500,000 of stockholders’ equity, while the company reported $1,895,000 as of March 31, 2026.

Tenon has 45 days, until July 6, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to do so. The notice does not immediately affect trading of the company’s common stock, but failure to regain compliance could eventually lead to delisting, subject to appeal rights before a Nasdaq Hearings Panel.

Tenon Medical, Inc. reported receiving a Nasdaq notice that it no longer meets the Nasdaq Capital Market’s minimum stockholders’ equity requirement. Nasdaq Listing Rule 5550(b)(1) requires at least $2,500,000 of stockholders’ equity, while the company reported $1,895,000 as of March 31, 2026.

Tenon has 45 days, until July 6, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to do so. The notice does not immediately affect trading of the company’s common stock, but failure to regain compliance could eventually lead to delisting, subject to appeal rights before a Nasdaq Hearings Panel.

Tenon Medical, Inc. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose to $1.38 million from $0.73 million, driven by more surgical procedures and added sales from the SImmetry+ SI Joint Fusion System. Gross margin improved to 69%, reflecting better overhead absorption.

The company still posted a net loss of $3.48 million and used $2.96 million of cash in operating activities. Cash and cash equivalents were $4.61 million. Management states there is substantial doubt about Tenon’s ability to continue as a going concern and discloses a Nasdaq notice for failing to maintain the $1.00 minimum bid price. During the quarter Tenon raised $4.3 million of gross proceeds from senior convertible promissory notes, adding a derivative liability, and later issued 276,228 shares for an acquisition milestone.

Tenon Medical, Inc. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Revenue rose to $1.38 million from $0.73 million, driven by more surgical procedures and added sales from the SImmetry+ SI Joint Fusion System. Gross margin improved to 69%, reflecting better overhead absorption.

The company still posted a net loss of $3.48 million and used $2.96 million of cash in operating activities. Cash and cash equivalents were $4.61 million. Management states there is substantial doubt about Tenon’s ability to continue as a going concern and discloses a Nasdaq notice for failing to maintain the $1.00 minimum bid price. During the quarter Tenon raised $4.3 million of gross proceeds from senior convertible promissory notes, adding a derivative liability, and later issued 276,228 shares for an acquisition milestone.

Geist Wyatt D. reported acquisition or exercise transactions in this Form 4 filing.

Tenon Medical, Inc. disclosed that on May 1, 2026 it issued 276,228 shares of common stock to SiVantage, Inc. under an Asset Purchase Agreement tied to a milestone achievement. Chief Innovation Officer Wyatt D. Geist has a 49.38% equity interest in SiVantage, giving him an indirect pecuniary interest in 136,401 of these shares, increasing his indirect holdings to 487,166 shares held by SiVantage. He also holds 157,569 shares directly and disclaims beneficial ownership of SiVantage’s shares except to the extent of his pecuniary interest.

Geist Wyatt D. reported acquisition or exercise transactions in this Form 4 filing.

Tenon Medical, Inc. disclosed that on May 1, 2026 it issued 276,228 shares of common stock to SiVantage, Inc. under an Asset Purchase Agreement tied to a milestone achievement. Chief Innovation Officer Wyatt D. Geist has a 49.38% equity interest in SiVantage, giving him an indirect pecuniary interest in 136,401 of these shares, increasing his indirect holdings to 487,166 shares held by SiVantage. He also holds 157,569 shares directly and disclaims beneficial ownership of SiVantage’s shares except to the extent of his pecuniary interest.

Tenon Medical, Inc. reported an equity milestone payment tied to its acquisition of assets from SiVantage, Inc. Under an Asset Purchase Agreement dated August 1, 2025, the company issued 276,228 shares of common stock to SiVantage on May 1, 2026 after a specified milestone was achieved.

The Form 4 for Chief Commercial Officer Nathaniel A. Grawey reflects his indirect pecuniary interest in these shares through his 24.69% equity interest in SiVantage, corresponding to 68,201 shares. After this award, he holds 243,584 shares indirectly via SiVantage and 239,281 shares directly of Tenon Medical common stock.

Tenon Medical, Inc. reported an equity milestone payment tied to its acquisition of assets from SiVantage, Inc. Under an Asset Purchase Agreement dated August 1, 2025, the company issued 276,228 shares of common stock to SiVantage on May 1, 2026 after a specified milestone was achieved.

The Form 4 for Chief Commercial Officer Nathaniel A. Grawey reflects his indirect pecuniary interest in these shares through his 24.69% equity interest in SiVantage, corresponding to 68,201 shares. After this award, he holds 243,584 shares indirectly via SiVantage and 239,281 shares directly of Tenon Medical common stock.

Tenon Medical, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable. Fourth quarter 2025 revenue reached $1.5 million, up 92% from $0.8 million a year earlier, with gross profit of $1.0 million and gross margin improving to 69% from 46%.

For the year ended December 31, 2025, revenue was $3.9 million, a 20% increase from $3.3 million, and gross profit was $2.4 million, or 60% of revenue, up from $1.7 million and 52%. Operating expenses for 2025 were $15.2 million, roughly flat with $15.5 million in 2024, leading to a narrower net loss of $12.6 million, or $1.70 per share, compared with a $13.7 million loss, or $11.26 per share. Cash and cash equivalents were $3.8 million as of December 31, 2025, down from $6.5 million, and the company reported no debt. Management highlighted FDA 510(k) clearance and initial procedures for its next-generation SImmetry+ SI Joint Fusion System as key milestones supporting future growth.

Tenon Medical, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable. Fourth quarter 2025 revenue reached $1.5 million, up 92% from $0.8 million a year earlier, with gross profit of $1.0 million and gross margin improving to 69% from 46%.

For the year ended December 31, 2025, revenue was $3.9 million, a 20% increase from $3.3 million, and gross profit was $2.4 million, or 60% of revenue, up from $1.7 million and 52%. Operating expenses for 2025 were $15.2 million, roughly flat with $15.5 million in 2024, leading to a narrower net loss of $12.6 million, or $1.70 per share, compared with a $13.7 million loss, or $11.26 per share. Cash and cash equivalents were $3.8 million as of December 31, 2025, down from $6.5 million, and the company reported no debt. Management highlighted FDA 510(k) clearance and initial procedures for its next-generation SImmetry+ SI Joint Fusion System as key milestones supporting future growth.

Tenon Medical, Inc. has been notified by Nasdaq that its common stock failed to meet the minimum closing bid price of $1.00 per share for 30 consecutive business days between January 9 and February 24, 2026, triggering a deficiency under Nasdaq’s bid price rule.

The company has 180 calendar days, until August 24, 2026, for its stock to close at or above $1.00 for at least 10 consecutive business days to regain compliance. If it still fails, Tenon may qualify for an additional 180-day period if it meets other Nasdaq listing standards and formally indicates how it plans to cure the deficiency, potentially through a reverse stock split.

Tenon’s shares continue to trade on The Nasdaq Capital Market under the symbol “TNON” while the company evaluates its options. However, failure to regain or maintain compliance could ultimately lead to delisting, though the company would have the right to appeal any delisting determination.

Tenon Medical, Inc. has been notified by Nasdaq that its common stock failed to meet the minimum closing bid price of $1.00 per share for 30 consecutive business days between January 9 and February 24, 2026, triggering a deficiency under Nasdaq’s bid price rule.

The company has 180 calendar days, until August 24, 2026, for its stock to close at or above $1.00 for at least 10 consecutive business days to regain compliance. If it still fails, Tenon may qualify for an additional 180-day period if it meets other Nasdaq listing standards and formally indicates how it plans to cure the deficiency, potentially through a reverse stock split.

Tenon’s shares continue to trade on The Nasdaq Capital Market under the symbol “TNON” while the company evaluates its options. However, failure to regain or maintain compliance could ultimately lead to delisting, though the company would have the right to appeal any delisting determination.

Tenon Medical, Inc. reported preliminary unaudited revenue ranges showing strong growth for 2025. Fourth quarter 2025 revenue is expected between $1.45 million and $1.48 million, which the company says is about 90% higher year over year compared with the fourth quarter of 2024.

For full year 2025, Tenon expects unaudited revenue between $3.91 million and $3.94 million, representing roughly 20% year-over-year growth versus 2024. The company plans to release full financial results after market close on March 19, 2026 and will host a conference call that day at 4:30 p.m. Eastern Time to discuss the results in more detail.

Tenon Medical, Inc. reported preliminary unaudited revenue ranges showing strong growth for 2025. Fourth quarter 2025 revenue is expected between $1.45 million and $1.48 million, which the company says is about 90% higher year over year compared with the fourth quarter of 2024.

For full year 2025, Tenon expects unaudited revenue between $3.91 million and $3.94 million, representing roughly 20% year-over-year growth versus 2024. The company plans to release full financial results after market close on March 19, 2026 and will host a conference call that day at 4:30 p.m. Eastern Time to discuss the results in more detail.

Tenon Medical, Inc. filed an 8-K dated September 23, 2025 that lists its publicly traded securities and records signatures and share-count figures for several named officers and directors. The document references Common Stock (par value $0.001) trading under the symbol TNON and Warrants trading under TNONW on The Nasdaq Stock Market. Individual entries show numeric holdings for Steven Foster, Richard Ginn, Stephen Hochschuler, MD, Ivan Howard, Kristine Jacques, and Robert Weigle, and the filing is executed by Steven M. Foster in his capacity as Chief Executive Officer and President.